Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMVW3I9)

Drug Name
RU 24969 Drug Info
Synonyms
RU 24969; 66611-26-5; RU-24969; 5-methoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole; UNII-2ISE72RACC; 2ISE72RACC; CHEMBL18785; 5-methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole; RU-24,969; KRVMLPUDAOWOGN-UHFFFAOYSA-N; NCGC00024867-01; Tocris-0912; GTPL23; Biomol-NT_000116; AC1Q4F1Q; SCHEMBL2359264; AC1L337E; BPBio1_000177; CHEBI:92005; BDBM81498; CTK1J4546; DTXSID40276045; MolPort-003-983-322; ZINC2568243; PDSP1_001623; PDSP2_001607; PDSP2_001601; PDSP1_001617; AKOS005135871; MCULE-3532976182; CS-3218; CAS_108028; API0006969
Cross-matching ID
PubChem CID
108029
ChEBI ID
CHEMBL18785
CAS Number
CAS 66611-26-5
TTD Drug ID
D03PJW

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.22 0.00e+0 34/36 (94.44%) PCNA;MCM5;POLE2;...
Ribosome biogenesis in eukaryotes 1.92 4.09e-3 52/108 (48.15%) NAT10;NOL6;DKC1;...
One carbon pool by folate 1.79 3.54e-2 15/20 (75%) TYMS;MTHFD1;MTHFD2L;...
Nucleotide excision repair 1.78 3.06e-2 40/47 (85.11%) PCNA;POLE2;RFC4;...
Mismatch repair 1.77 2.45e-2 22/23 (95.65%) PCNA;RFC4;RPA2;...
Cell cycle 1.75 2.45e-2 110/124 (88.71%) PCNA;MCM5;MYC;...
RNA transport 1.74 2.45e-2 128/186 (68.82%) EIF1AY;EIF3B;NXT2;...
Intestinal immune network for IgA production 1.71 3.06e-2 38/48 (79.17%) CXCR4;HLA-DQA1;TNFSF13;...
Systemic lupus erythematosus 1.69 3.99e-2 45/135 (33.33%) HLA-DQA1;C3;C1QA;...
Vibrio cholerae infection -1.81 3.16e-2 44/50 (88%) PDIA4;SEC61A1;ATP6V1D;...
ECM-receptor interaction -1.81 3.95e-2 80/88 (90.91%) SPP1;DAG1;AGRN;...
Glioma -1.85 2.43e-2 67/75 (89.33%) PDGFRB;HRAS;CALML5;...
Oxidative phosphorylation -1.91 1.83e-2 93/133 (69.92%) ATP5MG;SDHD;SDHA;...
Steroid biosynthesis -2.48 0.00e+0 19/20 (95%) SOAT1;LIPA;TM7SF2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H